Drugs / HM30181AK-US
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT03588039 | Oct 2018 → May 2023 | neoplasm | Athenex, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT04168957 | Oct 2017 → Aug 2019 | breast carcinoma | Athenex, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT02730481 | Mar 2016 → Mar 2021 | cancer | Athenex, Inc. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT03892018 Comparator | Aug 2019 → May 2023 | cancer | Athenex, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HM30181AK-US | “Oral paclitaxel will be supplied in capsules and oral HM30181AK-US will be supplied in tablets” NCT03588039 ↗3“Oraxol HM30181 methanesulfonate monohydrate - supplied as 15-mg HM30181AK-US tablets” NCT02730481 ↗ “Oraxol will be supplied as paclitaxel capsules and HM30181AK-US tablets.” NCT03892018 ↗ “Oraxol (oral paclitaxel + oral HM30181AK-US)” NCT04168957 ↗ |
| Known as | HM30181 methanesulfonate monohydrate | “Oraxol HM30181 methanesulfonate monohydrate - supplied as 15-mg HM30181AK-US tablets” NCT02730481 ↗ |
| Route | Oral | “oral HM30181AK-US will be supplied in tablets” NCT03588039 ↗ |